Laurence Bessac

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial

Gregory G. Schwartz, Laurence Bessac, Lisa G. Berdan et al. · American Heart Journal · 2014 · 409 citations · Full text

Reductions in Atherogenic Lipids and Major Cardiovascular Events

Kausik K. Ray, Henry N. Ginsberg, Michael H. Davidson et al. · Circulation · 2016 · 128 citations · Full text

Lower On‐Treatment Low‐Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials

Antonio J. Vallejo‐Vaz, Henry N. Ginsberg, Michael H. Davidson et al. · Journal of the American Heart Association · 2018 · 27 citations · Full text

Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control

Antonio J. Vallejo‐Vaz, Kausik K. Ray, Henry N. Ginsberg et al. · Atherosclerosis · 2019 · 26 citations · Full text

Alirocumab Treatment and Achievement of Non‐High‐Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials

Harold Bays, Lawrence A. Leiter, Helen M. Colhoun et al. · Journal of the American Heart Association · 2017 · 14 citations · Full text